A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
Active, not recruiting
Trial end date:
2022-07-08
Target enrollment:
Participant gender:
Summary
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of
ABT-263 under two different dosing schedules with the objective of defining the dose limiting
toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263
at the defined recommended Phase 2 dose to obtain additional safety information and a
preliminary assessment of efficacy. The Extension Study portion will allow active subjects to
continue to receive ABT-263 for up to 11 years after the last subject transitions with less
frequent study evaluations.